Clinical utility of the Oncomine Dx Target Test multi ‐CDx system and the possibility of utilizing those original sequence data

ConclusionEven if sufficient tumor samples are obtained, rareEGFR mutations (which are excluded from the ODxTT's genetic mutation list) might not be detected using the current ODxTT system due to the program used for sequence analysis. However, such rareEGFR mutations can still be accurately detected on ODxTT's sequence data using next-generation sequencing.

Source: Cancer Medicine - March 8, 2024 Category: Cancer & Oncology Authors: Ayaka Saito, Hideki Terai, Tae ‐Jung Kim, Katsura Emoto, Ryutaro Kawano, Kohei Nakamura, Hideyuki Hayashi, Hatsuyo Takaoka, Akihiko Ogata, Katsuhito Kinoshita, Fumimaro Ito, Lisa Shigematsu, Masahiko Okada, Takahiro Fukushima, Akifumi Mits Tags: RESEARCH ARTICLE Source Type: research